Chemical entities that kill senescent cells for use in treating age-related disease
US-10195213-B2 · Feb 5, 2019 · US
Chemical entities that kill senescent cells for use in treating age-related disease
US10426788B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10426788-B2 |
| Application number | US-201815915989-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 8, 2018 |
| Priority date | Mar 13, 2015 |
| Publication date | Oct 1, 2019 |
| Grant date | Oct 1, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Disclosed herein are compounds that are effective for treatment of various disease states associated with senescence. The disclosed compounds can be used to eliminate senescent cells for disease treatment. The dosing of the compounds includes both single administration and regimens of cycling dosages.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of killing a senescent cell, the senescent cell being characterized as a non-cancerous cell in replicative arrest, the method comprising contacting the senescent cell with an effective amount of a senolytic compound that is lethal to the senescent cell, wherein the senolytic compound is gambogic acid or a pharmaceutical salt thereof. 2. The method of claim 1 , wherein the senescent cell is a fibroblast. 3. The method of claim 1 , wherein the senescent cell is a preadipocyte. 4. The method of claim l, wherein the senescent cell is a chondrocyte. 5. A method of killing senescent cells in a mixed cell population, the senescent cells being characterized as non-cancerous cells in replicative arrest, the method comprising administering to the mixed cell population an effective amount of a senolytic compound, wherein the senolytic compound is gambogic acid or a a pharmaceutical salt thereof. 6. The method of claim 5 , wherein the mixed cell population is present in an organ or tissue. 7. The method of claim 5 , wherein the compound kills at least 25% of the senescent cells in the mixed cell population. 8. The method of claim 5 , wherein the compound is administered to the mixed cell population in a timed-release formulation.
Assignees
Inventors
Classifications
1,3-Thiazoles · CPC title
condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline · CPC title
Aldehydes · CPC title
Thidiazoles · CPC title
- A61K31/575Primary
substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10426788B2 cover?
- Disclosed herein are compounds that are effective for treatment of various disease states associated with senescence. The disclosed compounds can be used to eliminate senescent cells for disease treatment. The dosing of the compounds includes both single administration and regimens of cycling dosages.
- Who is the assignee on this patent?
- Unity Biotechnology Inc
- What technology area does this patent fall under?
- Primary CPC classification A61K31/575. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Oct 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).